Objective: In this study we assessed the potential beneficial effect of intranasal administration of mesenchymal stem cells (MSCs) to rotenone model of PD in C57bl/6 mice.

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the elderly affecting approximately 1% of the population over 60 years old. PD motor defects result from degeneration of dopaminergic neurons that project from the substantia nigra to the striatum. As the disease progresses, motor manifestation worsens. Until now there is no causal therapy available to slow down or halt disease progression just symptomatic intervention are available. Reduction of progression of PD to half will reduce PD cost to about third. Cell therapy may represent one of the promising therapeutic modalities for PD, yet, the best route of administration of the cells to the brain is still a subject of decades of scientific trials.

Methods: Thirty mice were divided into three equal groups; control, rotenone and rotenone plus intranasally administrated MSCs. Tested mice were subjected to behavioral assessment and after 70 days, ten days of administration of MSCs, animal were sacrificed under deep anesthesia. Photomicrographs for coronal sections of the substantia nigra and striatum were evaluated immunohistochemically regarding tyrosine hydroxylase antibodies binding.

Results: Results showed the effective delivery of MSCs to the brains of the mice. Together with that, MSCs were capable to counteract the toxic effect of rotenone on both pathological and behavioral levels.

Conclusions: Thus, this study warrants further investigation of intranasal route as therapeutic option for Parkinson’s disease patients.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-potential-therapeutic-effect-of-intranasal-administration-of-stem-cells-in-rotenone-model-of-parkinsons-disease-in-mice/